The rising impact of biomarkers in early clinical development
Drug Target Review
APRIL 7, 2025
The emergence and adoption of clinically relevant biomarkers is gradually presenting alternatives to MTD, particularly around therapies such as cell and gene therapy (CGT) and immunotherapy. Silver Spring (MD): Food and Drug Administration (US); 2016-. Clinical Pharmacology and Therapeutics. Bagyinszky E, et al.
Let's personalize your content